Tau2020 Global Conference

Washington, D.C.

A new meeting in the calendar, Tau2020, covered the biology and pathology of all tauopathies, both primary and secondary. Some of the 650 attendees saw it as an inflection point in tau research, getting researchers to think more broadly and bringing their collective knowledge to bear on a common problem. Highlights included a new staging scheme for tau progression in AD, new ligands for primary tauopathies, cryoEM structures for α-synuclein, and a receptor that facilitates spread of mutant tau in mouse models.

  1. Tau Receptor Identified on Cell Surface
  2. Primary Tauopathies Get New PET Ligands
  3. New at Tau2020: PET Detects First Traces of Tangles in Rhinal Cortex

Human Amyloid Imaging 2020

Miami, Florida

PET imaging is adding a new layer of understanding to scientists’ concept of Alzheimer’s disease pathogenesis and progression. At the 14th Human Amyloid Imaging conference, speakers detailed nuances in the relationship between plaques, tangles, and cognitive decline. They also described nascent efforts to tie pathology in specific brain regions to specific behavioral and cognitive symptoms. While HAI featured new data on the pros and cons of various tau tracers in development, the synaptic tracer UCB-J jumped to the fore. It appears to detect synapse loss throughout AD cortex, as well as in other neurodegenerative diseases such as frontotemporal dementia and progressive supranuclear palsy.


View all 5 articles on this conference

Clinical Trials on Alzheimer's Disease 2019

San Diego, California

Following up on its October surprise, Biogen showed more data at the Clinical Trials in Alzheimer’s Disease conference, arguing that disparities in drug exposure explained the puzzlingly different outcomes in its one positive and one negative aborted Phase 3 trials. Audience members were put off by the messiness of the data set and not fully convinced by the analysis, but the majority said they believed the general signal that the antibody may slow disease progression. The prevailing mood was one of hopefulness, with most agreeing the results validate the amyloid hypothesis and suggest that effective treatments for AD are within reach.

View all 9 articles on this conference

Society for Neuroscience Annual Meeting 2019

Chicago, Illinois

Organized around 10 major themes, this year’s annual meeting attracted almost 23,000 scientists. Sessions in the Neurodegenerative Disorders and Injury theme drew the largest crowd, featuring more than 2,700 of SfN’s total 14,000-plus presentations. Aβ, tau, and other protein pathologies dominated, but there was a renewed emphasis on gene therapy for neurological disorders. Tom Fagan brings you some highlights.

View all 3 articles on this conference

2019 DIAD Family Conference: Mutation, Participation, Innovation.

Los Angeles, California

On July 13, the day before the Alzheimer’s Association International Conference started in Los Angeles, 263 DIAN participants and their partners met in the same location with scientists, clinicians, research funders, and representatives of the association for a pre-meeting. They celebrated a shared commitment to use the scientific opportunities inherent in dominantly inherited Alzheimer’s disease toward a better understanding and clinical trials to prevent the disease. Four stories in this series showcase the resilience of DIAN participants, progress in AD genetics, a first look at emerging RNA-based therapies, and an update on DIAN clinical trials.

View all 4 articles on this conference